mpugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year ended December 31, 2012 and disclosed its primary objectives for 2013.
Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “During the past three years, we have successfully established one of the most impressive discovery pipelines in the biopharma industry.
